Peripheral Arterial Occlusive Disease News

This RSS feed URL is deprecated


This RSS feed URL is deprecated, please update. New URLs can be found in the footers at https://news.google.com/news

Mortality with HF Readmissions Penalty; A Consistent COMPASS; Diagnosing Sarcoidosis - MedPage Today



MedPage Today
 
Mortality with HF Readmissions Penalty; A Consistent COMPASS; Diagnosing Sarcoidosis 
MedPage Today
As in the main analysis of the COMPASS trial, addition of ultra low-dose rivaroxaban (Xarelto) to aspirin was significantly better than aspirin alone for the subgroup of patients with peripheral arterial disease (PAD) and the subgroup with stable ...

and more » 


Diabetic Foot Ulcer Therapeutics - Pipeline Analysis 2017 - Markets Insider



Diabetic Foot Ulcer Therapeutics - Pipeline Analysis 2017 
Markets Insider
Diabetic foot ulcer is categorized into two types namely; neuropathic foot where neuropathy dominates and neuroischemic foot where occlusive vascular disease is the main factor. Diabetic neuropathy, peripheral artery disease and consequent trauma of ...

 


Avinger Announces First Patient Enrolled in its IDE Study of the Pantheris Image-Guided Atherectomy System for ... - Nasdaq



Avinger Announces First Patient Enrolled in its IDE Study of the Pantheris Image-Guided Atherectomy System for ... 
Nasdaq
REDWOOD CITY, Calif., Oct. 19, 2017 (GLOBE NEWSWIRE) -- Avinger, Inc. (NASDAQ:AVGR), a leading developer of innovative treatments for Peripheral Artery Disease (PAD), today announced initiation of INSIGHT, a prospective, global, single arm, multi ...

and more » 


Short-term Implanted Electrodes Following Regenerative Peripheral Nerve Surgery for Improving Prosthetic Limb ... - Healio



Short-term Implanted Electrodes Following Regenerative Peripheral Nerve Surgery for Improving Prosthetic Limb ... 
Healio
Participants must not have other indwelling electronic implants. Participants must not have severe peripheral vascular occlusive disease, venous hypertension of the extremity or severe lymphedema of the extremity. Participants must not have an ...

 


Selectin Inhibition Justifies GlycoMimetics Investment - Seeking Alpha



Seeking Alpha
 
Selectin Inhibition Justifies GlycoMimetics Investment 
Seeking Alpha
Potential label expansion opportunities include intermittent claudication, peripheral artery disease, and other disorders mediated by inflammatory cytokines. The market for peripheral artery disease is expected to reach $3.4 billion by 2022. GLYC also ...
GLYC GlycoMimetics, Inc. Stock Quote - Finviz Finviz
Glycomimetics, Inc. - GLYC - Stock Price Today - Zacks Zacks Investment Research

all 31 news articles » 


Self-Expanding Peripheral Vascular Stents Market Plying for Significant Growth During 2024 - MilTech



Self-Expanding Peripheral Vascular Stents Market Plying for Significant Growth During 2024 
MilTech
The global market for self-expanding peripheral vascular stents is expected to grow at a significant CAGR due to high incidence and increase diagnosis rate of peripheral vascular disease. Increasing incidence of cardiac disorders, lifestyle changes ...

and more » 


Remote Endarterectomy Devices Market Information and Industry Trends in 2017-2027 - MilTech



Remote Endarterectomy Devices Market Information and Industry Trends in 2017-2027 
MilTech
Remote Endarterectomy is basically used for the treatment of long-segmented superficial femoral artery (SFA) occlusive disease. ... Remote Endarterectomy is used in the peripheral vascular surgery to eliminate plaque from an occluded femoral artery.

 


New ESC Guideline on Peripheral Arterial Disease - Medscape



Medscape
 
New ESC Guideline on Peripheral Arterial Disease 
Medscape
BARCELONA, SPAIN ? Patients with peripheral arterial disease (PAD) should receive multidisciplinary management from a "vascular team" that involves specialties outside of cardiovascular medicine and surgery, say novel European guidelines on PAD that ...

 


Bayer to Present Pulmonary Arterial Hypertension Data at the 2017 Annual Meeting of the American College of Chest ... - PR Newswire (press release)



Bayer to Present Pulmonary Arterial Hypertension Data at the 2017 Annual Meeting of the American College of Chest ... 
PR Newswire (press release)
WHIPPANY, N.J., Oct. 24, 2017 /PRNewswire/ -- Bayer announced today that data from its pulmonary disease franchise will be presented in scientific sessions at the 2017 annual meeting of the American College of Chest Physicians (CHEST 2017), October 28 ...

and more » 


COMPASS: Rivaroxaban Reduces CV and Limb Events in PAD - Medscape



WHTC
 
COMPASS: Rivaroxaban Reduces CV and Limb Events in PAD 
Medscape
... rivaroxaban (Xarelto, Bayer/Janssen Pharmaceuticals) plus aspirin 100 mg daily showed significant reductions in both major cardiovascular and limb events, including amputations, in patients with peripheral arterial disease (PAD) in the COMPASS trial.
Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease - New England Journal of Medicine New England Journal of Medicine

all 61 news articles »